HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray.

Abstract
Recent evidence shows that the proportion of poorly differentiated prostate carcinoma (Gleason pattern [GP] 4/5) is a surrogate factor for biochemical failure after radical prostatectomy (RP). However, little is known about specific molecular and cytogenetic changes in this aggressive component of localized prostate cancer. We constructed a tissue microarray containing areas of GP 3 and 4 from formalin-fixed radical prostatectomy specimens of 39 patients with Gleason score 7 carcinoma (>or=50% GP 4), known pathologic staging parameters (stage < T3b), and biochemical failure data (mean follow-up, 30 months; range, 5 to 74 months). Interphase fluorescent in situ hybridization (FISH) was performed on 5-microm microarray sections using pericentromeric probes to chromosomes 7, 8, and 17 and probes for the HER-2/neu and epidermal growth factor receptor (EGFR) genes. Low-level amplification of HER-2/neu was found in 26% of cases (3 to 5 signals per nucleus, corrected for chromosome 17 aneusomy). Aneusomy of chromosomes 7, 8, and 17 was identified in 21%, 15%, and 5% of cases, respectively. All aberrations occurred almost exclusively in GP 4 carcinoma (8 of 8 aneusomies 7, 2 of 2 trisomies 17, 9 of 10 HER-2/neu amplifications, and 5 of 6 aneusomies 8; P < .001). The presence of HER-2/neu amplification was associated with high tumor volume (>2.0 cm(3), P = 0.004). Among patients with negative surgical margins, gain of chromosome 7 was associated with biochemical failure after RP (P =.004, log-rank). Amplification of the EGFR gene occurred in only 1 case (3%). Significant differences in HER-2/neu amplification and gain of chromosomes 7, 8, and 17 were detected between GP 4 prostate carcinoma and GP 3. The frequency of aberrations increased with tumor volume. Chromosome 7 abnormalities may play an important role in cancer progression in margin-negative patients. EGFR amplification was rare, suggesting that this oncogene is not altered at the gene copy number level.
AuthorsM Skacel, A H Ormsby, J D Pettay, E K Tsiftsakis, L S Liou, E A Klein, H S Levin, C D Zippe, R R Tubbs
JournalHuman pathology (Hum Pathol) Vol. 32 Issue 12 Pg. 1392-7 (Dec 2001) ISSN: 0046-8177 [Print] United States
PMID11774175 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright 2001 by W.B. Saunders Company
Chemical References
  • DNA, Neoplasm
  • ErbB Receptors
  • Prostate-Specific Antigen
Topics
  • Adenocarcinoma (genetics, mortality, pathology, surgery)
  • Aged
  • Aged, 80 and over
  • Aneuploidy
  • Chromosomes, Human, Pair 17
  • Chromosomes, Human, Pair 7
  • Chromosomes, Human, Pair 8
  • DNA, Neoplasm (analysis)
  • ErbB Receptors (genetics)
  • Gene Amplification
  • Genes, erbB-2 (genetics)
  • Histocytological Preparation Techniques
  • Humans
  • Immunoenzyme Techniques
  • In Situ Hybridization
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Prostate-Specific Antigen (analysis)
  • Prostatic Neoplasms (genetics, mortality, pathology, surgery)
  • Survival Rate
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: